Recent News

• 03.06.2025 - Elutia Q4 2024 Financial Results Call
• 03.06.2025 - Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out
• 02.20.2025 - Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025
• 02.03.2025 - Elutia Announces $15.0 Million Registered Direct Offering
• 01.14.2025 - Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand
• 01.06.2025 - Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners
• 12.02.2024 - Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.
• 11.14.2024 - Elutia Q3 2024 Financial Results Call
• 11.14.2024 - Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

Recent Filings

• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2025 - 8-K Current report
• 02.04.2025 - EX-99.1 EX-99.1
• 02.03.2025 - 8-K Current report
• 02.03.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.11.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2024 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]